A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events (MACE) in Overweight and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR/Bupropion SR

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events (MACE) in Overweight and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR/Bupropion SR

Discontinued
Phase of Trial: Phase III

Latest Information Update: 20 May 2017

At a glance

  • Drugs Naltrexone/bupropion (Primary)
  • Indications Obesity
  • Focus Adverse reactions; Registrational
  • Acronyms Light; Light Study
  • Sponsors Orexigen Therapeutics; Takeda
  • Most Recent Events

    • 20 May 2017 Results assessing the effect of Naltrexone/Buproplon on body weight of overweight and obese participants with elevated cardiovascular risk, presented at the 24th European Congress on Obesity.
    • 20 May 2017 Results analysing adverse events in participants receiving antidepressant medication along with Naltrexone/bupropion in this study, presented at the 24th European Congress on Obesity.
    • 03 Nov 2016 Data from this trial will be presented at the Obesity Week medical conference 2016, according to an Orexigen Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top